Cell-permeable peptide inhibitors of JNK novel blockers of beta-cell death

Citation
C. Bonny et al., Cell-permeable peptide inhibitors of JNK novel blockers of beta-cell death, DIABETES, 50(1), 2001, pp. 77-82
Citations number
42
Categorie Soggetti
Endocrynology, Metabolism & Nutrition","Endocrinology, Nutrition & Metabolism
Journal title
DIABETES
ISSN journal
00121797 → ACNP
Volume
50
Issue
1
Year of publication
2001
Pages
77 - 82
Database
ISI
SICI code
0012-1797(200101)50:1<77:CPIOJN>2.0.ZU;2-U
Abstract
Stress conditions and proinflammatory cytokines activate the c-Jun NH2-term inal kinase (JNK), a member of the stress-activated group of mitogen-activa ted protein kinases (MAPKs). We recently demonstrated that inhibition of JN K signaling with the use of the islet-brain (IB) 1 and 2 proteins prevented interleukin (IL)1 beta -induced pancreatic beta -cell death. Bioactive cel l-permeable peptide inhibitors of JNK were engineered by linking the minima l 20-amino acid inhibitory domains of the IB proteins to the 10-amino acid HIV-TAT sequence that rapidly translocates inside cells. Kinase assays indi cate that the inhibitors block activation of the transcription factor c-Jun by JNK. Addition of the peptides to the insulin-secreting beta TC-3 cell l ine results in a marked inhibition of IL-1 beta -induced c-jun and c-fos ex pression. The peptides protect beta TC-3 cells against apoptosis induced by IL-1 beta. All-D retro-inverso peptides penetrate cells as efficiently as the L-enantiomers, decrease c-Jun activation by JNK, and remain highly stab le inside cells. These latter peptides confer full protection against IL-1 beta -induced apoptosis for up to 2 weeks of continual treatment with IL-1 beta. These data establish these bioactive cell-permeable peptides as poten t pharmacological compounds that decrease intracellular JNK signaling and c onfer long-term protection to pancreatic beta -cells from IL-1 beta -induce d apoptosis.